Addendum
Guselkumab (plaque psoriasis) - Addendum to Commission A17-60
Report documents
-
Addendum
Guselkumab (plaque psoriasis) - Addendum to Commission A17-60
Dossier assessment
Indication:
Adults with moderate to severe plaque psoriasis with inadequate response to other systemic treatments or with contraindication or intolerance
Result of dossier assessment:
Based on the study data subsequently submitted, there is now proof of a major added benefit in this therapeutic indication
Additional information
Federal Joint Committee (G-BA)
2018-05-17 A G-BA decision was published.
Project details
- Project no.
- A18-24
- Commission
- Commission awarded on 09.04.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Skin and hair
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Guselkumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed